PDAC - Pancreatic Ductal Adenocarcinoma

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)

Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma